Abstract：
UNASSIGNED: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease of unknown cause with a dismal prognosis. Nintedanib and Pirfenidone are approved worldwide for the treatment of IPF, but they only slow the rate of functional decline and disease progression. Therefore, there is an urgent need for more efficacious and better tolerated drugs.
UNASSIGNED: αvβ6 and αvβ1 are two integrins overexpressed in fibrotic tissue, which play a critical role in the development of lung fibrosis. They act by converting transforming growth factor (TGF)-β, one of the most important profibrotic cytokine, in its active form. Here, we summarize and critically discuss the potential of a dual αvβ6/αvβ1 integrin inhibitor for the treatment of IPF.
UNASSIGNED: Bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, has the potential to slow or even halt disease progression in IPF. Indeed, the strong pre-clinical rationale and promising early phase clinical trial data have raised expectations.
UNASSIGNED: αvβ6 and αvβ1 are two integrins overexpressed in fibrotic tissue, which play a critical role in the development of lung fibrosis. They act by converting transforming growth factor (TGF)-β, one of the most important profibrotic cytokine, in its active form. Here, we summarize and critically discuss the potential of a dual αvβ6/αvβ1 integrin inhibitor for the treatment of IPF.
UNASSIGNED: Bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, has the potential to slow or even halt disease progression in IPF. Indeed, the strong pre-clinical rationale and promising early phase clinical trial data have raised expectations.
摘要：
■特发性肺纤维化（IPF）是一种病因不明的慢性进行性间质性肺病，预后不良。Nintedanib和吡非尼酮在世界范围内被批准用于治疗IPF，但它们只能减缓功能下降和疾病进展的速度。因此,迫切需要更有效和耐受性更好的药物.
■αvβ6和αvβ1是两种在纤维化组织中过度表达的整合素,在肺纤维化的发展中起着至关重要的作用。它们通过转化转化生长因子（TGF）-β，最重要的促纤维化细胞因子之一，以其活跃的形式。这里,我们总结并批判性地讨论了双重αvβ6/αvβ1整合素抑制剂治疗IPF的潜力。
■Bexotegrast,双重αvβ6/αvβ1整合素抑制剂，有可能减缓甚至阻止IPF中的疾病进展。的确,强有力的临床前理论基础和有前景的早期临床试验数据提高了人们的预期.
■αvβ6和αvβ1是两种在纤维化组织中过度表达的整合素,在肺纤维化的发展中起着至关重要的作用。它们通过转化转化生长因子（TGF）-β，最重要的促纤维化细胞因子之一，以其活跃的形式。这里,我们总结并批判性地讨论了双重αvβ6/αvβ1整合素抑制剂治疗IPF的潜力。
■Bexotegrast,双重αvβ6/αvβ1整合素抑制剂，有可能减缓甚至阻止IPF中的疾病进展。的确,强有力的临床前理论基础和有前景的早期临床试验数据提高了人们的预期.
